Delphinus Medical Technologies Announces New VP of Engineering
21 Mayo 2024 - 6:05AM
Business Wire
Rama Gundlapalli brings decades of engineering
and R&D experience
Delphinus Medical Technologies, a pioneering medical imaging
company that developed the SoftVue™ Breast Tomographic Ultrasound,
announced today that Rama Gundlapalli has joined the company as
Vice President of Engineering. Mr. Gundlapalli brings more than 30
years of experience in product development and engineering, having
worked in startup, small and fortune 500 companies and applying
knowledge in research and development to build out successful
commercial product pipelines.
“Rama’s vast experience in commercial development and helping to
build numerous successful product pipelines will serve Delphinus
well as we advance our SoftVue technology,” said Scott White,
president and CEO, Delphinus Medical Technologies, Inc. “We
continue to grow our team with industry leaders and I’m excited to
have Rama’s experience in delivering successful products to market.
Rama’s background in clinical imaging specific to hardware and
software platforms will certainly expedite the adoption of the
SoftVue into the breast healthcare market.”
Gundlapalli comes to Delphinus after most recently holding the
position of senior director of research collaborations at Siemens
Healthineers. He supervised the Advanced Therapies US/Canada
collaboration Team with a focus on driving leadership
transformation and executing innovation and product development
strategies across interventional neurology, pulmonology,
cardiology, liver cancer and skeletal diseases. Prior to Siemens,
Mr. Gundlapalli worked at Northgate Technologies Inc. helping
develop and commercialize laparoscopic insufflators and lithotripsy
systems; CareFusion (acquired by BD) and DePuy Synthes (J&J
MedTech) leading the development and launch of their high-flex
total knee systems. In addition, Mr. Gundlapalli has nurtured his
entrepreneurial side with three startups of his own.
“I’m excited to be part of Delphinus Medical Technologies and
support our mission. The team is dedicated and passionate about
making SoftVue the market leading solution for early detection of
breast cancer in women with dense breasts,” said Rama Gundlapalli.
“Like many, my family has a history of breast cancer, and it is my
goal to support bringing SoftVue to healthcare providers across the
country in order to help save lives.”
SoftVue is approved by the U.S. Food and Drug Administration
(FDA) as an adjunct to mammography for screening women with dense
breasts. At least 40% of US women have dense breasts, and
compounding the increased risk, dense breast tissue like cancer,
typically appears white on a mammogram, making it more challenging
to detect cancer early. When paired with mammography, SoftVue has
been shown to identify up to 20 percent more cancers, while also
reducing false positives and decreasing unnecessary call-backs and
biopsies in women with dense breasts.
Delphinus continues to leverage the breakthrough performance of
SoftVue to expand commercialization and is adding to its commercial
infrastructure to support national implementation of robust dense
breast screening programs to benefit patients in targeted
accounts.
About Delphinus Medical Technologies, Inc.
Headquartered in Novi, Michigan, Delphinus Medical Technologies,
Inc., is a pioneering medical imaging company that developed
SoftVue™, featuring the first circular array transducer technology.
The patented technology is a 3D whole-breast ultrasound tomography
system that delivers no radiation, requires no compression, and
images the entire breast with a single scan. To learn more, visit
our website and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521195818/en/
Sam Choinski Pazanga Health Communications
schoinski@pazangahealth.com (860) 301-5058